113 related articles for article (PubMed ID: 2987362)
21. Epicutaneous application of leukotriene B4 induces patterns of tenascin and a heparan sulfate proteoglycan epitope that are typical for psoriatic lesions.
Seyger MM; van Pelt JP; van den Born J; Latijnhouwers MA; de Jong EM
Arch Dermatol Res; 1997 May; 289(6):331-6. PubMed ID: 9209678
[TBL] [Abstract][Full Text] [Related]
22. 5-Lipoxygenase activation in psoriasis: a dead issue?
Ford-Hutchinson AW
Skin Pharmacol; 1993; 6(4):292-7. PubMed ID: 8198815
[TBL] [Abstract][Full Text] [Related]
23. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis.
Brain S; Camp R; Dowd P; Black AK; Greaves M
J Invest Dermatol; 1984 Jul; 83(1):70-3. PubMed ID: 6330213
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous application of leukotriene B4 as an in vivo model of psoriasis-like skin inflammation: an immunohistological study.
Hendriks AG; Keijsers RR; Seyger MM; van de Kerkhof PC; van Erp PE
Skin Pharmacol Physiol; 2014; 27(3):120-6. PubMed ID: 24401330
[TBL] [Abstract][Full Text] [Related]
25. The effect of topical retinoids on the leukotriene-B4-induced migration of polymorphonuclear leukocytes into human skin.
Wozel G; Chang A; Zultak M; Czarnetzki BM; Happle R; Barth J; van de Kerkhof PC
Arch Dermatol Res; 1991; 283(3):158-61. PubMed ID: 1651071
[TBL] [Abstract][Full Text] [Related]
26. Specific inhibition of leukotriene B4 (LTB4)-induced neutrophil emigration by 20-hydroxy LTB4: implications for the regulation of inflammatory responses.
Pettipher ER; Salter ED; Breslow R; Raycroft L; Showell HJ
Br J Pharmacol; 1993 Sep; 110(1):423-7. PubMed ID: 8220903
[TBL] [Abstract][Full Text] [Related]
27. Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasis.
Wong E; Barr RM; Cunningham FM; Mistry K; Woollard PM; Mallet AI; Greaves MW
Br J Clin Pharmacol; 1986 Dec; 22(6):627-32. PubMed ID: 3032226
[TBL] [Abstract][Full Text] [Related]
28. A study of the photodegradation of leukotriene B4 by ultraviolet irradiation (UVB, UVA).
Millar B; Green C; Ferguson J; Raffle EJ; Macleod TM
Br J Dermatol; 1989 Feb; 120(2):145-52. PubMed ID: 2538137
[TBL] [Abstract][Full Text] [Related]
29. Distribution of skin-derived antileucoproteases (SKALP) in the marginal zone of the spreading psoriatic lesion.
Van de Kerkhof PC; Kuppens LH; Van Vlijmen Y; Schalkwijk J
Br J Dermatol; 1991 Jan; 124(1):10-2. PubMed ID: 1847066
[TBL] [Abstract][Full Text] [Related]
30. Leukotriene B4-like material in scale of psoriatic skin lesions.
Brain SD; Camp RD; Cunningham FM; Dowd PM; Greaves MW; Black AK
Br J Pharmacol; 1984 Sep; 83(1):313-7. PubMed ID: 6091827
[TBL] [Abstract][Full Text] [Related]
31. Dithranol modulates the leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukocytes.
Chang A; Alkemade H; van de Kerkhof PC
J Invest Dermatol; 1989 Jun; 92(6):806-8. PubMed ID: 2542415
[TBL] [Abstract][Full Text] [Related]
32. Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice.
Andoh T; Kuraishi Y
Eur J Pharmacol; 1998 Jul; 353(1):93-6. PubMed ID: 9721045
[TBL] [Abstract][Full Text] [Related]
33. The response of uninvolved skin of patients with psoriasis to single and repeated applications of dithranol cream: an immunohistochemical assessment.
Swinkels OQ; Prins M; van Vlijmen-Willems IM; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
Skin Pharmacol Appl Skin Physiol; 2002; 15(6):385-92. PubMed ID: 12476012
[TBL] [Abstract][Full Text] [Related]
34. The inter-relation between inflammation and epidermal proliferation in normal skin following epicutaneous application of leukotriene-B4--an immunohistochemical study.
de Jong EM; van Erp PE; van Vlijmen IM; van de Kerkhof PC
Clin Exp Dermatol; 1992 Nov; 17(6):413-20. PubMed ID: 1336720
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of action of leukotriene B4: intracellular calcium redistribution in rabbit neutrophils.
Naccache PH; Molski TF; Borgeat P; Sha'afi RI
J Cell Physiol; 1984 Jan; 118(1):13-8. PubMed ID: 6317702
[TBL] [Abstract][Full Text] [Related]
36. Generation of leukotrienes from normal epidermis and their demonstration in cutaneous disease.
Rosenbach T; Grabbe J; Möller A; Schwanitz HJ; Czarnetzki BM
Br J Dermatol; 1985 Jul; 113 Suppl 28():157-67. PubMed ID: 2990517
[TBL] [Abstract][Full Text] [Related]
37. The treatment of tinea with topically applied leukotriene B4.
Katayama H
Prostaglandins; 1987 Dec; 34(6):797-804. PubMed ID: 2835788
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological effects of a specific leukotriene B(4) receptor antagonist (VML 295) on blood leukocytes, cutaneous inflammation and epidermal proliferation.
Seegers BA; Andriessen MP; van Hooijdonk CA; de Bakker ES; van Vlijmen-Willems IM; Parker GL; van Erp PE; van de Kerkhof PC
Skin Pharmacol Appl Skin Physiol; 2000; 13(2):75-85. PubMed ID: 10754455
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor-enhanced leukotriene B4 generation and chemotaxis in human neutrophils.
Meyer JD; Yurt RW; Duhaney R; Hesse DG; Tracey KJ; Fong YM; Verma M; Shires GT; Dineen P; Lowry SF
Arch Surg; 1988 Dec; 123(12):1454-8. PubMed ID: 2847685
[TBL] [Abstract][Full Text] [Related]
40. Effect of inhaled leukotriene B4 alone and in combination with prostaglandin D2 on bronchial responsiveness to histamine in normal subjects.
Black PN; Fuller RW; Taylor GW; Barnes PJ; Dollery CT
Thorax; 1989 Jun; 44(6):491-5. PubMed ID: 2548300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
